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The interactions between genetics 
and early childhood nutrition 
influence adult cardiometabolic risk 
factors
Carol A. Wang1,2, John R. Attia1,2, Stephen J. Lye3, Wendy H. Oddy4, Lawrence Beilin5, 
Trevor A. Mori5, Claire Meyerkort6 & Craig E. Pennell1,2*
It is well established that genetics, environment, and interplay between them play a crucial role 
in adult disease. We aimed to evaluate the role of genetics, early life nutrition, and the interaction 
between them, on optimal adult health. As part of a large international consortium (n ~ 154,000), we 
identified 60 SNPs associated with both birthweight and adult disease. Utilising the Raine Study, we 
developed a birthweight polygenic score (BW-PGS) based on the 60 SNPs and examined relationships 
between BW-PGS and adulthood cardiovascular risk factors, specifically evaluating interactions 
with early life nutrition. Healthy nutrition was beneficial for all individuals; longer duration of any 
breastfeeding was particularly associated with lower BMI and lower Systolic Blood Pressure in those 
with higher BW-PGS. Optimal breastfeeding offers the greatest benefit to reduce adult obesity and 
hypertension in those genetically predisposed to high birthweight. This provides an example of how 
precision medicine in early life can improve adult health.
Non-communicable diseases (NCDs) represent the largest burden of mortality, accounting for 41 M deaths 
(71% of annual global mortality) in  20171 with cardiovascular disease (CVD) and diabetes being the two most 
significant  contributors2. Geoffrey Rose argued that most cases of disease come from the large proportion of the 
population at low risk rather than the small proportion at high  risk3. This has been the foundation of public health 
campaigns that target the entire population; however, despite decades of public health campaigns, the global 
rates of some of the major risk factors for CVD (obesity, hypertension, dyslipidaemia and diabetes) continue to 
 increase1. It is clear that alternative approaches beyond public health campaigns are required to tackle the global 
challenge of NCDs. Precision medicine is an approach to medicine where medical decisions and treatments pre-
scribed are tailored in accordance with the recipients’ characteristics as opposed to a one-size-fits-all approach. 
Over the last decade, it is becoming more evident that precision medicine could potentially be the tool needed 
to identify those for whom more targeted preventative measures are warranted.
There is substantial evidence that early life exposures program the fetus and infant for lifelong health or 
 disease4. This concept, termed the Developmental Origins of Health and Disease (DOHaD) initially focused 
on birthweight as a surrogate for intrauterine  exposures5,6; more recent evidence has demonstrated that genet-
ics plays a fundamental role in the relationship between early life events and adult  disease7,8. Developmental 
plasticity, the property of a given genotype to produce different phenotypes in response to different environ-
mental conditions, is greatest in the first 1000 days of  life9. The integration of the key role of genetics in DOHaD 
and developmental plasticity offers the unique opportunity to utilise precision medicine approaches to reduce 
NCDs through primary prevention. With this knowledge, enhanced prevention or therapeutic strategies can be 
particularly targeted to those for whom it will be most efficacious, thus reducing unnecessary treatments and 
saving costs to the health  system10.
There is a large body of evidence that adverse antenatal and postnatal environments could program the fetus 
and infant for lifelong health or  disease4; however, not all individuals exposed develop poor outcomes as adults 
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suggesting the potential role of genetics in the development of adult  disease7,8. These studies demonstrate the 
need to examine the role of genetics, the environment, and the interplay between them to tackle the global chal-
lenge of NCDs. We utilised data from the Raine Study and evaluated the associations between genetics, early life 
nutrition, and adult cardiovascular risk factors, specifically assessing the interaction between genetics and early 
life nutrition on adult health outcomes.
In this report we provide evidence that the primary prevention of NCDs is possible through DOHaD, devel-
opmental plasticity, and precision medicine. The aim of this study was to evaluate the potential for targeted 
nutritional intervention in early life to reduce the risk of adult disease.
Results
Study characteristics. There were 1328 participants available for analyses. Maternal and early life char-
acteristics, and adult measures are summarised by sex in Table 1. On average, the Raine Study male Gen2 par-
ticipants were heavier and longer at birth and had greater weight gain in the first year compared to their female 
counterparts. As adults, males were taller, heavier and had higher systolic blood pressure (SBP) than females but 
lower percent body fat on DEXA scan. Further, males had higher fasting glucose and lower fasting insulin than 
females. Lipids were similar in both sexes in young adults.
The development of a birthweight polygenic score. The use of polygenic scores (PGS) has been 
shown to provide more power with less bias than single SNP approaches. These scores have an expanding role 
in predicting disease and can potentially enable a better understanding of aetiology of disease. In addition, PGS 
have also been used to test for genome-wide Gene–Gene and Gene-Environment  interactions11,12. As part of 
a meta-analysis within a large international consortium (n ~ 154,000), we identified 60 SNPs associated with 
 birthweight7 (Supplementary Table 1) and developed a birthweight PGS (BW-PGS; see Methods) for each study 
participant. The BW-PGS was then used as a genetic measure in the evaluation of associations between genetics, 
early life nutrition, and adult cardiovascular risk factors.
Breastfeeding in individuals who are genetically predisposed to high birthweight reduces the 
risk of obesity. There was no association between percent optimal birthweight (POBW) and body mass 
index (BMI) at age 22 (p = 0.063, Table 2). The duration of any breastfeeding and Eating Assessment in Toddlers 
score at 1 year  (EAT1) were associated with reduced adult BMI (p = 0.050 and p = 0.010, respectively). There was 
no evidence of effect modification of breastfeeding on BMI by POBW (p = 0.43, Table 2, Fig. 1A, Supplementary 
Fig. 1A).
Similar to POBW, no association was observed between BW-PGS and BMI (p = 0.64. Table 2). Healthy early 
nutrition beyond breastfeeding at one year of age  (EAT1 score; p = 0.0084, Table 2) and three years of age  (EAT3 
score; p = 0.043, Supplementary Table 2) were associated with lower BMI. There was an interaction between 
breastfeeding and BW-PGS on BMI, such that lower BMI was observed in those that were breastfed longer and 
had higher BW-PGS (p = 0.037, Table 2, Fig. 2A, Supplementary Fig. 1B).
When obesity was trichotomised using clinical definitions of overweight (BMI ≥ 25  kg/m2) and 
obese (BMI ≥ 30 kg/m2), the effect modification of breastfeeding on the outcome by BW-PGS persisted 
(breastfeeding*BW-PGS interaction p-values p = 0.00096 and p = 0.0079 respectively for overweight and obese 
outcomes; Supplementary Table 3, Fig. 3A and B).
With early life nutrition beyond breastfeeding, the associations between  EAT1 score and clinical definitions 
of overweight and obese persisted while associations between  EAT3 score and clinical definitions of overweight 
and obese were no longer significant  (EAT1 p = 0.024;  EAT3 p = 0.066; Supplementary Table 4).
Somewhat similar results were observed for association analyses for percent body fat measured by DEXA 
scan for healthy early life nutrition (βEAT1 score = −0.09, p = 0.0054; Supplementary Table 5) and breastfeeding 
(βbreastfeeding = −0.09, p = 0.054; Supplementary Table 5). Furthermore, there was a suggestive association for effect 
modification of breastfeeding by BW-PGS (p = 0.069; Supplementary Table 5; Supplementary Figs. 2A and 3A).
As part of sensitivity analyses, we examined the imputed dataset and demonstrated the effect modification 
of breastfeeding on BMI by BW-PGS (p = 0.038, Supplementary Table 6) was consistent to that of complete case 
analysis.
Breastfeeding in individuals who are genetically predisposed to high birthweight reduces the 
risk of elevated blood pressure. There was no association between POBW and SBP or BW-PGS and SBP. 
Longer periods of breastfeeding were associated with higher SBP in young adults (p = 0.041, Table 3). Healthy 
nutrition beyond breastfeeding at one year of age,  EAT1 score, was associated with lower SBP (Table 3). No asso-
ciation was observed with SBP and improved  EAT3 score (p = 0.51, Supplementary Table 7). There was no effect 
modification for breastfeeding on SBP by POBW (p = 0.95, Table 3, Fig. 1B). In contrast, there was an interaction 
between breastfeeding duration and BW-PGS on SBP (p = 0.030, Table 3, Fig. 2B, Supplementary Fig. 1D), such 
that higher SBP was observed in those with a low BW-PGS and who were breastfed for shorter duration. This 
result, however, was not replicated in sensitivity analyses when we evaluated the effect modification of breast-
feeding on SBP by BW-PGS (p = 0.15, Supplementary Table 8) in the imputed dataset and was likely due to the 
small effect size of breastfeeding on SBP. When examining SBP as a dichotomous outcome (SBP ≥ 120 mmHg), 
those with high BW-PGS who were breastfed for more than six months had lower SBP than those with shorter 
periods of breastfeeding and similar BW-PGS (p = 0.0022, Supplementary Table 9, Fig. 3C).  EAT1 score, but not 
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There were no associations between DBP and POBW or DBP and BW-PGS. Some associations were dem-
onstrated between duration of breastfeeding and  EAT1 score with DBP (Supplementary Table 11). No effect 
modification was demonstrated for breastfeeding on DBP by POBW (p = 0.30) or BW-PGS (p = 0.25).
Healthy nutrition beyond breastfeeding in early life reduces the risk of diabetes. Fasting 
serum insulin was inversely associated with POBW and  EAT1 score; no associations were demonstrated with 
BW-PGS or breastfeeding or  EAT3 score (Table 4, Supplementary Table 12). Furthermore, no effect modification 
was demonstrated for breastfeeding on fasting insulin by POBW or BW-PGS (p = 0.51 and p = 0.81 respectively, 
Table 4, Figs. 1C and 2C). Paradoxically, data on glucose and HOMA-IR (Supplementary Tables 13 and 14 and 
Supplementary Figs. 2C, 2D, 3C and 3D) showed a main effect of POBW but not BW-PGS; however, there was 
no effect modification for breastfeeding on these outcomes by either POBW or BW-PGS.
Table 1.  Demographic table for study participants. F denotes fasting.
All Study Participants (N = 1328) Females (N = 640) Males (N = 688)
Mean (SD) or N (%) Mean (SD) or N (%) Mean (SD) or N (%)
Maternal Characteristics
Age at pregnancy (in years) 28.80 (5.79) 28.70 (5.84) 28.90 (5.74)
Completed high school N (%) 572 (43.10) 267 (41.78) 305 (44.33)
Nulliparous, N (%) 622 (46.84) 294 (45.94) 328 (47.67)
Height (in m) 1.64 (0.07) 1.64 (0.07) 1.64 (0.06)
Pre-pregnancy weight (in kg) 60.68 (12.19) 60.70 (12.30) 60.70 (12.10)
Pre-pregnancy BMI (in kg/m2) 22.53 (4.32) 22.50 (4.28) 22.60 (4.35)
Weight gain in pregnancy as a percentage of pre-
pregnancy weight 23.63 (10.51) 23.50 (11.00) 23.70 (10.00)
Diabetes, N (%) 42 (3.21) 18 (2.85) 24 (3.55)
Hypertension, N (%) 336 (25.36) 154 (24.06) 182 (26.57)
Ever smoked during pregnancy, N (%) 463 (34.86) 236 (36.88) 227 (32.99)
Early Life Characteristics
Polygenic Birth Weight Score (BW-PGS) 65.77 (3.78) 65.70 (3.76) 65.80 (3.79)
Gestational age at birth (days) 279 (8.96) 279 (8.81) 279 (9.10)
Birth Length (cm) 49.54 (2.07) 49.20 (1.97) 49.90 (2.10)
Birth Weight (g) 3469.45 (450.83) 3412.00 (442.00) 3523.00 (453.00)
Percent Optimal Birth Weight (POBW) 99.00 (11.61) 99.10 (11.50) 98.90 (11.70)
Duration of any breastfeeding (months) 8.02 (7.14) 7.92 (7.19) 8.11 (7.09)
Duration of exclusive breastfeeding (months) 3.13 (1.95) 3.09 (1.97) 3.17 (1.94)
Weight gain in the first year of life as a percentage of 
birth weight 202.74 (43.69) 197.00 (43.70) 208.00 (43.20)
Characteristics at age 20
Percentage Body Fat 30.25 (12.77) 39.60 (9.01) 21.60 (9.08)
Bone Mass Density 1.08 (0.11) 1.03 (0.09) 1.13 (0.11)
Characteristics at age 22
Currently smoking, N (%) 118 (15.49) 55 (13.82) 63 (17.31)
Height (in m) 1.73 (0.09) 1.66 (0.06) 1.80 (0.07)
Weight (in kg) 76.37 (17.53) 70.90 (17.70) 81.70 (15.60)
BMI (in kg/m2) 25.24 (5.15) 25.20 (5.82) 25.20 (4.43)
Waist (in cm) 83.68 (13.75) 81.20 (15.20) 86.10 (11.80)
Hip (in cm) 100.36 (11.21) 101.00 (12.80) 100.00 (9.41)
Waist-Hip ratio 0.83 (0.08) 0.80 (0.08) 0.86 (0.06)
Systolic BP (in mmHg) 119 (11.22) 114 (9.77) 123 (10.80)
Diastolic BP (in mmHg) 67 (7.07) 67.30 (7.00) 66.70 (7.14)
GlucoseF (in mmol/l) 5.02 (0.85) 4.86 (0.40) 5.17 (1.11)
InsulinF (in mU/ml) 8.39 (5.48) 9.31 (6.25) 7.52 (4.46)
HOMA-IRF 1.89 (1.37) 2.06 (1.59) 1.73 (1.10)
Total  CholesterolF (in mmol/l) 4.61 (0.83) 4.71 (0.83) 4.50 (0.82)
TriglyceridesF (in mmol/l) 1.09 (0.48) 1.07 (0.45) 1.11 (0.51)
HDL-CholesterolF (in mmol/l) 1.36 (0.34) 1.48 (0.39) 1.24 (0.24)
LDL-CholesterolF (in mmol/l) 2.74 (0.71) 2.74 (0.67) 2.75 (0.75)
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Healthy nutrition beyond breastfeeding in early life reduces the risk of dyslipidaemia. LDL-C 
was not associated with POBW, BW-PGS, breastfeeding or  EAT3 score (Table 5, Figs. 1D and 2D, Supplementary 
Table 15); inverse associations were observed between LDL-C and  EAT1 score (Table 5). Data for total choles-
terol, triglycerides and HDL-C (Supplementary Tables 16–18) showed no effect modification for breastfeeding 
on any of these lipid measure by POBW or BW-PGS (Supplementary Figs. 2E-G and 3E-G).
There was no evidence of differential effects of healthy nutrition by sex. No differential effect of 
breastfeeding by sex and BW-PGS was found in three-way interaction analyses for BMI and SBP (Supplementary 
Tables 19–22); neither was there a significant association when the modifying effect of breastfeeding on BMI and 
SBP, via sex, was examined in the two-way interactions for sex and breastfeeding (Supplementary Tables 23–24).
Discussion
In this study, we demonstrated the critical role and potential for nutritional intervention in the first year of life 
to reduce cardiovascular risk factors, as surrogates for the components of adult metabolic syndrome. Specifi-
cally, our results suggested an interaction between duration of any breastfeeding and genetics; greater benefit for 
breastfeeding was present in the subgroup with increased BW-PGS. Individuals with high BW-PGS had a greater 
reduction in the incidence of overweight and obesity and lower systolic blood pressure with increased duration 
of any breastfeeding than those with low BW-PGS. There was a 25% and 35% reduction in adult overweight and 
obesity, respectively, in those with high BW-PGS with increased duration of any breastfeeding. In contrast, there 
was no significant difference in those with low BW-PGS with increased duration of any breastfeeding. Similarly, 
the probability of having elevated systolic blood pressure (≥ 120 mmHg) was approximately halved in those with 
high BW-PGS with increased duration of any breastfeeding, whereas there was no significant difference in those 
with low BW-PGS with increased duration of any breastfeeding. While encouraging breastfeeding in all mothers 
is a good public health strategy, our results suggest that precision medicine, in the form of actively supporting 
longer duration of any breastfeeding in the subgroup at highest genetic risk, has the potential to place individuals 
on trajectories to health rather than disease. While it appears the differential effect of breastfeeding by BW-PGS 
is only present in risk of obesity and elevated blood pressure and not present in insulin and LDL-c, we propose 
that one possible explanation is that the genetic influence is stronger for BMI and blood pressure, while postnatal 
environment influences are perhaps greater for insulin and LDL-c.
Next, we demonstrated a beneficial effect of healthy nutrition beyond breastfeeding, with associations more 
likely to be significant in the earlier years of life rather than later. This is shown through the 20–25% reduction in 
the probability of adult overweight/obesity with every standard deviation increase in dietary quality score at one 
year of age  (EAT1 score), and no association between the risk of overweight/obesity and dietary quality score at 
three years of age  (EAT3 score). Similarly, there is an approximate 20% reduction in the risk of SBP ≥ 120 mmHg 
with every standard deviation increase in  EAT1 score and no association between SBP and  EAT3 score. This 
reinforces the critical importance of nutrition beyond breastfeeding in the first year of life.
Table 2.  Association analyses for body mass index (kg/m2). γ POBW = Percent Optimal Birth Weight 
(standardised); † Duration of BF = Duration of any breastfeeding (mean-centred); ‡  EAT1 score = quality of 
early life nutrition in first year of life; § BW-PGS = birth weight polygenic score (standardised); δ adjustment for 
population stratification; α Model 1 examines the effect of duration of breastfeeding adjusting for POBW, sex 
and  EAT1 score; β Model 2 examines the effect modification of duration of breastfeeding by POBW adjusting 
for sex and  EAT1 score; ε Model 3 examines the effect of duration of breastfeeding adjusting for BW-PGS, sex, 
 EAT1 score and the first two principal components [PCs] (estimates not presented); ϕ Model 4 examines the 
effect modification of duration of breastfeeding by BW-PGS adjusting for sex,  EAT1 score and the first two 
principal components [PCs] (estimates not presented).
Percent Optimal Birth Weight (POBW) Model  1α Model  2β
Predictors Estimate (95% CI) P Estimate (95% CI) P
Intercept 27.62 (25.69–29.55)  < 0.0001 27.70 (25.76–29.65)  < 0.0001
POBWγ 0.40 (−0.02 to 0.82) 0.063 0.41 (−0.01 to 0.83) 0.056
Duration BF (months)† −0.06 (−0.12 to 0.00) 0.050 −0.06 (−0.12 to 0.00) 0.064
Sex (M) 0.16 (−0.66 to 0.98) 0.70 0.12 (−0.71 to 0.95) 0.78
EAT1  score‡ −0.06 (−0.10 to −0.01) 0.010 −0.06 (−0.10 to −0.01) 0.0091
POBW * Duration BF −0.02 (−0.07 to 0.03) 0.43
Birthweight Polygenic Score (BW-PGS) Model  3ε Model  4ϕ
Predictors Estimate (95% CI) P Estimate (95% CI) P
Intercept 27.67 (25.73–29.62)  < 0.0001 27.62 (25.68–29.55)  < 0.0001
BW-PGS§ 0.10 (−0.33 to 0.53) 0.64 0.18 (−0.25 to 0.61) 0.058
Duration BF (months)† −0.05 (−0.11 to 0.01) 0.10 −0.05 (−0.11 to 0.01) 0.11
Sex (M) 0.19 (−0.63 to 1.02) 0.64 0.24 (−0.58 to 1.06) 0.57
EAT1  score‡ −0.06 (−0.10 to −0.02) 0.0084 −0.06 (−0.10 to −0.01) 0.0090
BW-PGS * Duration BF −0.06 (−0.11 to −0.00) 0.037
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Evidence over the last three decades has established an association between adverse intrauterine environment 
(low birthweight) and adult disease. This relationship was first noted by David Barker and has been successfully 
replicated in numerous  studies13. Despite this body of evidence, risk with low birthweight was not demonstrated 
in our study. The failure to replicate these findings is possibly due to the relatively young age of the cohort and 
limited variance within the cardiovascular risk factors within our study participants.
The Early Growth Genetics (EGG) consortium recently released a GWAS of  birthweight8 with an increased 
number of SNPs identified. The proportion of variance explained in birthweight by the updated genetics score 
based on these SNPs were, however, half of that of which explained by the BW-GRS used in this study. Consid-
ering a greater proportion of variance explained in birthweight weight by BW-GRS used in this study, we are 
confident that the results presented in this study potentially provides improved statistical power, and is a better 
instrumental variable compared to the SNPs in the recent 2019 GWAS paper.
In the recent years, it has been suggested that increased disease risk could also be present in babies born 
large-for-gestational-age13. A recent meta-analysis by Knop et. al. replicated the original inverse association 
with blood pressure but suggested a ‘J-shaped’ relationship with the risk of developing diabetes mellitus and 
cardiovascular  disease14. Further, two separate meta-analyses have reported the highest risk of overweight and 
obesity among large-for-gestational-age  babies5,6. A growing body of evidence suggests DOHaD is largely driven 
by  genetics7,8. As part of two large consortium studies involving more than 100 K individuals from across 35 
Figure 1.  The relationship between duration of any breastfeeding and health measures for POBW that is one 
standard deviation above the mean, and for POBW that is one standard deviation below the mean. F denotes 
fasting. (A): Body mass index (BMI) at 22 years of age; (B): Systolic blood pressure (SBP) at 22 years of age; (C): 
Fasting insulin levels at 22 years of age; and (D): Fasting low density lipoprotein cholesterol (LDL-c) at 22 years 
of age (Figure generated using ggplot2 in Refs.37,38).
6
Vol:.(1234567890)
Scientific Reports |        (2021) 11:14826  | https://doi.org/10.1038/s41598-021-94206-4
www.nature.com/scientificreports/
studies, we demonstrated genetic variants associated with birthweight were also associated with BMI, SBP and 
risk for later life adult metabolic  disease7,8, suggesting birthweight could potentially be a surrogate for genetic 
variations associated with adult disease.
Over the last quarter century, emphasis has been placed upon an individual’s environmental exposure before 
two years of age. The end of the second year of life marks the end of the first 1000 days since conception, and is 
a crucial period where environmental exposures could have the potential to alter an individual’s trajectory for 
future health outcome. The findings from our study suggest healthy nutrition beyond breastfeeding is beneficial 
for all individuals, with effects becoming non-significant with age. This is demonstrated through the reduction 
in probability of adult obesity and elevated blood pressure and with improved dietary quality score at one year of 
age compared to score at three years of age. This observation suggests the critical importance of healthy nutrition 
in the first 1–2 years of life; however, there may exist limitations with capturing true diet quality given early life 
dietary scores were computed based on self-reported recall of food intake over a 24-h period.
The World Health Organisation (WHO) advocates exclusive breastfeeding in the first six months of life, and 
high rates of exclusive breastfeeding have been shown to be associated with benefits to the mother, child and 
 society15. The rates of exclusive breastfeeding in the first six months, however, still remain low and far from reach-
ing the global nutrition target for 2025 of at least 50%16. We demonstrated that good quality nutrition is beneficial 
for all individuals and the greatest benefit appears to be most prevalent before one year of age. Additionally, 
Figure 2.  The relationship between duration of any breastfeeding and health measures for BW-PGS that is one 
standard deviation above the mean, and for BW-PGS that is one standard deviation below the mean. F denotes 
fasting. (A): Body mass index (BMI) at 22 years of age; (B): Systolic blood pressure (SBP) at 22 years of age; (C): 
Fasting insulin levels at 22 years of age; and (D): Fasting low density lipoprotein cholesterol (LDL-c) at 22 years 
of age (Figure generated using ggplot2 in Refs.37,38).
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for the first time, we showed that this benefit is differential, i.e. there is greater benefit for breastfeeding in the 
subset of the population with increased BW-PGS; furthermore the genetic risk score was a better proxy of risk 
than birthweight.
A recent review on breastfeeding and its potential in reducing the risks of NCDs has reported conflicting 
 data17. In addition, meta-analyses of the protective effects of breastfeeding on adult NCDs suggested only modest 
benefit with limited clinical and public health  importance18,19. These could indicate that although breastfeed-
ing may have a modest benefit overall, there may be a particular benefit in a subset of the population identified 
through precision medicine. In a study by Abarin et. al., the duration of exclusive breastfeeding had a differential 
effect on the trajectory of BMI in childhood, depending on whether they were carriers of the ‘AT’ or ‘AA’ genotype 
of the FTO variant (rs9939609)20. In a separate study, Wu et. al. demonstrated the potential of utilising a polygenic 
score for BMI to identify and emphasise the importance of exclusive breastfeeding at targeted individuals to 
reduce the incidence of obesity and its associated non-communicable diseases in both children and  adolescents21. 
Figure 3.  Predicted probability of adverse adult health outcomes at 22 years of age by BW-PGS group (High vs 
Low) and Duration of any Breastfeeding (< 6 months vs ≥ 6 months). A low BW-PGS is defined as those in the 
0-80th percentile of the BW-PGS within the Raine Study participants, while a high BW-PGS is defined as those 
in the highest quintile (80-100th percentile) of the BW-PGS within the Raine Study participants. (A): Predicted 
probability of being obese (BMI ≥ 25 kg/m2) at 22 years of age by BW-PGS and duration of breastfeeding; 
(B): Predicted probability of being obese (BMI ≥ 30 kg/m2) at 22 years of age by BW-PGS and duration of 
breastfeeding; (C): Predicted probability of being an elevated systolic BP (SBP ≥ 120 mmHg) at 22 years of age by 
BW-PGS and duration of breastfeeding. (Figure generated using ggplot2 in Refs.37,38).
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The polygenic score, developed from a set of variants, mimics fine-mapping by capturing variants which could 
explain precise genetic and biological mechanisms underlying the phenotype of  interest22; this provides more 
power with less bias than single SNP approaches.
Table 3.  Association analyses for systolic blood pressure (mmHg). γ POBW = Percent Optimal Birth Weight 
(standardised); † Duration of BF = Duration of any breastfeeding (mean-centred); ‡  EAT1 score = quality of 
early life nutrition in first year of life; § BW-PGS = birth weight polygenic score (standardised); δ adjustment for 
population stratification; α Model 1 examines the effect of duration of breastfeeding adjusting for POBW, sex 
and  EAT1 score; β Model 2 examines the effect modification of duration of breastfeeding by POBW adjusting 
for sex and  EAT1 score; ε Model 3 examines the effect of duration of breastfeeding adjusting for BW-PGS, sex, 
 EAT1 score and the first two principal components [PCs] (estimates not presented); ϕ Model 4 examines the 
effect modification of duration of breastfeeding by BW-PGS adjusting for sex,  EAT1 score and the first two 
principal components [PCs] (estimates not presented).
Percent Optimal Birth Weight (POBW) Model  1α Model  2β
Predictors Estimate (95% CI) P Estimate (95% CI) P
Intercept 118.15 (114.46–121.83)  < 0.0001 118.16 (114.46–121.86)  < 0.0001
POBWγ −0.69 (−1.50 to 0.12) 0.096 −0.68 (−1.50 to 0.13) 0.099
Duration BF (months)† 0.12 (0.01–0.23) 0.038 0.12 (0.01–0.23) 0.039
Sex (M) 9.50 (7.93–11.08)  < 0.0001 9.50 (7.91–11.09)  < 0.0001
EAT1  score‡ −0.10 (−0.18 to −0.02) 0.015 −0.10 (−0.18 to −0.02) 0.015
POBW * Duration BF −0.00 (−0.10 to 0.1) 0.95
Birthweight Polygenic Score (BW-PGS) Model  3ε Model  4ϕ
Predictors Estimate (95% CI) P Estimate (95% CI) P
Intercept 118.17 (114.47–121.87)  < 0.0001 117.93 (114.23–121.62)  < 0.0001
BW-PGS§ 0.07 (−0.75 to 0.88) 0.87 0.20 (−0.62 to 1.02) 0.63
Duration BF (months)† 0.11 (0.00–0.23) 0.048 0.12 (0.01–0.23) 0.041
Sex (M) 9.49 (7.91–11.06)  < 0.0001 9.59 (8.01–11.16)  < 0.0001
EAT1  score‡ −0.10 (−0.18 to −0.02) 0.015 −0.10 (−0.18 to −0.02) 0.020
BW-PGS * Duration BF −0.12 (−0.22 to −0.01) 0.030
Table 4.  Association analyses for Fasting Serum Insulin (Natural Log Transformed). γ POBW = Percent 
Optimal Birth Weight (standardised); † Duration of BF = Duration of any breastfeeding (mean-centred); ‡  EAT1 
score = quality of early life nutrition in first year of life; § BW-PGS = birth weight polygenic score (standardised); 
δ adjustment for population stratification; α Model 1 examines the effect of duration of breastfeeding adjusting 
for POBW, sex and  EAT1 score; β Model 2 examines the effect modification of duration of breastfeeding by 
POBW adjusting for sex and  EAT1 score; ε Model 3 examines the effect of duration of breastfeeding adjusting 
for BW-PGS, sex,  EAT1 score and the first two principal components [PCs] (estimates not presented); ϕ Model 
4 examines the effect modification of duration of breastfeeding by BW-PGS adjusting for sex,  EAT1 score and 
the first two principal components [PCs] (estimates not presented).
Percent Optimal Birth Weight (POBW) Model  1α Model  2β
Predictors Estimate (95% CI) P Estimate (95% CI) P
Intercept 2.28 (2.11–2.45)  < 0.0001 2.29 (2.11–2.46)  < 0.0001
POBWγ −0.05 (−0.09 to −0.01) 0.011 −0.05 (−0.09 to −0.01) 0.013
Duration BF (months)† −0.00 (−0.01 to 0.00) 0.23 −0.00 (−0.01 to 0.00) 0.26
Sex (M) −0.19 (−0.26 to −0.12)  < 0.0001 −0.19 (−0.27 to −0.12)  < 0.0001
EAT1  score‡ −0.00 (−0.01 to −0.00) 0.032 −0.00 (−0.01 to −0.00) 0.030
POBW * Duration BF −0.00 (−0.01 to 0.00) 0.51
Birthweight Polygenic Score (BW-PGS) Model  3ε Model  4ϕ
Predictors Estimate (95% CI) P Estimate (95% CI) P
Intercept 2.23 (2.08–2.43)  < 0.0001 2.26 (2.08–2.43)  < 0.0001
BW-PGS§ −0.02 (−0.05 to 0.02) 0.45 −0.02 (−0.05 to 0.02) 0.43
Duration BF (months)† −0.00 (−0.01 to 0.00) 0.13 −0.00 (−0.01 to 0.00) 0.13
Sex (M) −0.19 (−0.26 to −0.11)  < 0.0001 −0.19 (−0.26 to −0.11)  < 0.0001
EAT1  score‡ −0.00 (−0.01 to 0.00) 0.067 −0.00 (−0.01 to 0.00) 0.066
BW-PGS * Duration BF 0.00 (−0.00 to 0.01) 0.81
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Precision medicine, a shift from a one-size-fits-all approach, utilises an individual’s characteristics to guide a 
clinician in providing the most appropriate treatment at the right time. Precision medicine has been successfully 
adopted in the field of oncology and reproductive health; however, there has been limited application in life-
course health to identify individuals at the highest risk for non-communicable diseases. The life-course approach 
to health acknowledges crucial and sensitive periods in life, and their relevance in future health outcomes. The 
first 1000 days in life is one of the early life critical windows for developmental plasticity. Timely introduction 
of appropriate interventions during sensitive periods will allow maximum benefit on specific health outcomes. 
The life-course approach hence capitalises on the phenomenon of developmental plasticity where simple and 
early interventions can be targeted at individuals at increased risk to alter health trajectory for optimal health. 
We believe that while public health campaigns to the general population should continue, precision medicine 
provides a way to identify those at highest risk and allows supplemental and targeted intervention to those likely 
to benefit the most.
The strengths of this study include the availability of a unique prospective longitudinal study cohort, with 
genetic data and 22 years of phenotype data including nutrition, cardiovascular risk factors and body composi-
tion. The Raine Study is representative of the general Western Australian population allowing generalisability to 
the broader  population23. Our study, however, was limited by the sample size for detecting small genetic associa-
tion. The young age and limited variance within the cardiovascular risk factors potentially resulted in the small 
effect sizes that were seen in our study. Lastly, our findings may not apply to other ethnic populations as most of 
the study participants were of Caucasian descent.
Conclusion
Using a longitudinal study population with rich genetic and phenotype data, we have demonstrated the impor-
tance of nutrition in the first year of life and, for the first time, the particular benefit of breastfeeding in the highest 
risk group (as determined by a polygenic risk score for BW) to reduce the risk of later life non-communicable 
diseases. Our findings indicate that longer duration of breastfeeding is particularly beneficial for individuals 
with high BW-PGS, leading to lower BMI and SBP in young adults. These data suggest that optimal breastfeed-
ing in the first year of life could offer the greatest benefit to reduce adult disease in those at high genetic risk. 
This suggests potential for precision medicine in the first 1000 days of life to place individuals on trajectories to 
better health in adulthood.
Methods
Study population. The Raine Study is a prospective pregnancy cohort of 2900 mothers recruited between 
1989–1991 (https:// www. raine study. org. au/)24. Recruitment took place at Western Australia’s major perinatal 
centre, King Edward Memorial Hospital, and nearby private practices. Women who had sufficient English lan-
guage skills, an expectation to deliver at King Edward Memorial Hospital, and an intention to reside in Western 
Australia to allow for future follow-up of their child were eligible for the study.
Table 5.  Association analyses for Fasting Low-Density-Lipoprotein-Cholesterol (mmol/L). γ POBW = Percent 
Optimal Birth Weight (standardised); † Duration of BF = Duration of any breastfeeding (mean-centred); ‡  EAT1 
score = quality of early life nutrition in first year of life; § BW-PGS = birth weight polygenic score (standardised); 
δ adjustment for population stratification; α Model 1 examines the effect of duration of breastfeeding adjusting 
for POBW, sex and  EAT1 score; β Model 2 examines the effect modification of duration of breastfeeding by 
POBW adjusting for sex and  EAT1 score; ε Model 3 examines the effect of duration of breastfeeding adjusting 
for BW-PGS, sex,  EAT1 score and the first two principal components [PCs] (estimates not presented); ϕ Model 
4 examines the effect modification of duration of breastfeeding by BW–PGS adjusting for sex,  EAT1 score and 
the first two principal components [PCs] (estimates not presented).
Percent Optimal Birth Weight (POBW) Model  1α Model  2β
Predictors Estimate (95% CI) P Estimate (95% CI) P
Intercept 3.15 (2.89–3.42)  < 0.0001 3.13 (2.87–3.40)  < 0.0001
POBWγ −0.02 (−0.08 to 0.04) 0.52 −0.02 (−0.08 to 0.03) 0.43
Duration BF (months)† 0.00 (−0.01 to 0.01) 0.56 0.00 (−0.01 to 0.01) 0.66
Sex (M) 0.02 (−0.10 to 0.13) 0.79 0.03 (−0.08 to 0.14) 0.62
EAT1  score‡ −0.01 (−0.02 to −0.00) 0.0017 −0.01 (−0.02 to −0.00) 0.0022
POBW * Duration BF 0.01 (−0.00 to 0.01) 0.14
Birthweight Polygenic Score (BW-PGS) Model  3ε Model  4ϕ
Predictors Estimate (95% CI) P Estimate (95% CI) P
Intercept 3.15 (2.88–3.41)  < 0.0001 3.13 (2.87–3.40)  < 0.0001
BW-PGS§ 0.01 (−0.04 to 0.07) 0.65 0.02 (−0.04 to 0.08) 0.52
Duration BF (months)† 0.00 (−0.01 to 0.01) 0.63 0.00 (−0.01 to 0.01) 0.61
Sex (M) 0.02 (−0.10 to 0.13) 0.76 0.02 (−0.09 to 0.13) 0.71
EAT1  score‡ −0.01 (−0.02 to −0.00) 0.0019 −0.01 (−0.02 to −0.00) 0.0024
BW-PGS * Duration BF −0.01 (−0.01 to 0.00) 0.20
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The primary carers (Gen1) completed questionnaires regarding their respective study child, and the children 
(Gen2) had physical examinations at ages 1, 2, 3, 5, 8, 10, 14, 17, 18, 20, and 22. Ethics approval for the original 
pregnancy cohort and subsequent follow-ups were granted by the Human Research Ethics Committee of King 
Edward Memorial Hospital, Princess Margaret Hospital, the University of Western Australia, and the Health 
Department of Western Australia. Parents, guardians and young adult participants provided written informed 
consent either before enrolment of at data collection at each follow-up. This study included a subset of the original 
cohort that had genetic data, were Caucasian, singleton, born at term, and without evidence of fetal anomaly 
(n = 1328). It was previously demonstrated that the study population is representative of the general population 
in Western  Australia23. All research was performed in accordance with the approved guidelines.
Measures of early life determinants. Gestational age (GA) was determined by either date of last men-
strual period (LMP) or fetal biometry at the 18-week gestation ultrasound (USS) examination. If the difference 
between methods was greater than seven days, GA was derived from USS; otherwise, the LMP method was used. 
Birthweight was retrieved from hospital records, and percent optimal birthweight (POBW) was calculated as the 
ratio of observed growth to optimal growth (based on GA, fetal sex, and maternal characteristics including age, 
parity and height)25.
Early life nutrition. Duration of exclusive breastfeeding and of any breastfeeding (in months) were com-
puted based on self-reported duration of breastfeeding, and the age of the first introduction of other forms 
of milk and/or solids. The quality of early life nutrition in the first 1000 days of life beyond breastfeeding was 
assessed at cohort reviews performed at ages one, two and three, through a self-reported detailed recollection 
of several food groups and beverage intake in the study child over a 24-h period, that was completed by the 
primary carer and quantified as a dietary score (Eating Assessment in Toddlers (EAT) score—EAT1,  EAT2 and 
 EAT3 scores for ages one, two and three, respectively). In brief, the EAT scores were based on the Youth Healthy 
Eating  Index26, ranged between 0 to 70, with higher scores indicating healthier dietary quality in the study child. 
Details of the computation of the EAT scores are described  elsewhere27. The quality of early life nutrition beyond 
breastfeeding was assessed through a self-reported detailed recollection of food and beverage intake in the study 
child over a 24-h period, analysed using the dietary analysis program FoodWorks® (Professional Version 5, 2007, 
Xyris Software, Brisbane), evaluated and scored by a team of nutritionists. Only EAT scores with a 24-h period 
recall for dietary intake were valid and used in this study.
Assessment of adult outcomes. Four areas of adult metabolic syndrome including obesity, hyperten-
sion, diabetes, and dyslipidaemia were investigated using appropriate cardiovascular risk factors as surrogates. 
Obesity was assessed via body mass index (BMI) and DEXA scan measured body composition; hypertension via 
systolic and diastolic blood pressures (SBP, DBP); diabetes via glucose, insulin and calculated insulin-resistance 
measured using the homeostasis-model-assessment-for-insulin-resistance (HOMA-IR); and dyslipidaemia via 
low-density-lipoprotein-cholesterol (LDL-C), total-cholesterol, triglycerides, and high-density-lipoprotein-cho-
lesterol (HDL-C).
All adult outcomes were measured by trained research staff. Height and weight were measured with partici-
pants dressed in light clothing. Height was measured (to the nearest 0.1 cm) with the participant standing in the 
anatomical position, palms facing forward, with shoes off, heels, buttocks and head against the board using a 
wall-mounted stadiometer, while weight was measured (to the nearest 100 g) using a chair scale. Body mass 
index (BMI) was calculated using the formula BMI = weight (kg)
height2 (m2)
 . Body composition was assessed using a Norland 
XR-36 densitometer (Norland Medical Systems, Inc., Fort Atkinson, WI, USA) which provided estimates of fat 




∗ 100 . Resting SBP and DBP (mmHg) were measured using an oscillometric sphyg-
momanometer with an appropriate cuff size for arm circumference. Six sets of readings were recorded, once 
every 2 min following a 5-min rest period. Average SBP and DBP were calculated after discarding the first set of 
reading. Blood samples were collected to investigate biochemistry measures including plasma glucose, serum 
insulin, triglycerides, total-cholesterol, HDL-C and LDL-C. Plasma glucose (mmol/L) was measured using an 
automated Technicon Axon analyser (Bayer Diagnostics, Sydney, Australia) using a hexokinase method; while 
serum insulin (mU/ml) was measured using an automated radioimmunoassay (Tosoh, Tokyo, Japan). Homeo-
s t a s i s - m o d e l - a s s e s s m e nt  f or  In s u l i n  R e s i s t a n c e  ( HOM A- I R )  w a s  c a l c u l a t e d  by 
HOMA− IR =
Insulin(inmIU/ml)∗glucose(inmmol/l)
22.5  . Total-Cholesterol (mmol/L) and triglycerides (mmol/L) were 
determined enzymatically on the Cobas MIRA analyser (Roche Diagnostics) with reagents from Trace Scientific 
(Melbourne, Australia), while HDL-C (mmol/L) was determined on a heparin-manganese supernatant. LDL-C 
(mmol/L) was calculated using the Friedewald formula, valid for Triglycerides < 3.5 mmol/L28.
The anthropometric, blood pressure and biochemical outcomes were measured at the 22-year follow-up; 
body composition was measured at the 20-year follow-up. Biochemical measures were included in this study if 
participants completed an overnight fast.
Genetics data. The Raine Study Gen2 participants were genotyped on an Illumina 660 W Quad Array at the 
Centre for Applied Genomics, Toronto, Canada. Quality control (QC) of the Genome-Wide-Association-Study 
(GWAS) genotyped data were performed as per standard protocol. In brief, a total of 1593 Raine Study Gen2 
participants were genotyped on an Illumina 660 Quad Array, which included 657,366 genetic variants, consisting 
of ~ 560,000 single-nucleotide-polymorphisms (SNPs) and ~ 95,000 copy number variants (CNVs), at the Cen-
tre for Applied Genomics, Toronto, Canada. Plate controls and replicates with a higher proportion of missing 
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data were excluded before individuals were assessed for low genotyping success (> 3% missing), excessive het-
erozygosity, gender discrepancies between the core data and genotyped data, and cryptic relatedness (π > 0.1875, 
in between second- and third-degree relatives—e.g. between half-siblings and cousins). At the SNP level, the 
SNP data were cleaned using  plink29 following the Wellcome Trust Case—Control Consortium  protocol30. The 
exclusion criteria for SNPs included: Hardy–Weinberg-Equilibrium p < 5.7 ×  10–7; call-rate < 95%; minor-allele-
frequency < 1%; and SNPs of possible strand ambiguity (i.e. A/T and C/G SNPs). The cleaned GWAS data were 
imputed using MACH  software31 across the 22-autosomes and X-chromosome against the 1000 Genome Project 
Phase I version  332. A total of 1494 individuals with 535,632 SNPs remained after genotype QC; imputation 
resulted in 30,061,896 and 1,264,4493 SNPs across the 22-autosomes and X-chromosome, respectively. Principal 
components (PCs) analysis was carried out, using SMARTPCA from v.3.0 of  EIGENSOFT33, on the cleaned 
genotyped data, where PCs were generated for purposes of adjusting for population stratification in all genetic 
analyses.
Development of the birthweight polygenic score (BW-PGS). Genome-wide association analyses 
have enabled us to identify genetic variants associated with a wide range of traits; however, these effect sizes are 
usually small with low predictive  power22,34. Several studies demonstrated increased predictive power with the 
use of polygenic score (PGS), a metric computed by summing the risk alleles corresponding to the phenotype of 
interest in each individual, when compared to a small number of genome-wide significant  SNPs11,35. In addition 
to identifying and understanding potential aetiology of disease, PGS have also been used to test for genome-wide 
Gene*Gene and Gene-Environment  interactions11,12.
As part of a meta-analysis within a large international consortium (n ~ 154,000), we identified 60 SNPs 
associated with birthweight and adult  disease7 (Supplementary Table 1). These SNPs data were extracted from 
the Raine Study Gen2 participants, re-coded to correspond with increasing birthweight, weighted using the 
beta-coefficients reported in the meta-analysis, summed and re-scaled before the BW-PGS was calculated for 
each study participant.
Statistical methods. All measures of adult outcomes and variables in this study were analysed as continu-
ous measures unless otherwise stated. Prior to any analyses, the natural logarithmic-transformation was applied 
to all adult outcomes which deviated from a normal distribution to approximate normality; duration of breast-
feeding was centred at its mean; POBW and BW-PGS were standardised.
Four multivariate linear regression models were fitted to examine the effect of early life nutrition on adult 
outcomes. In the first model, the effect of early life nutrition was examined after adjusting for POBW, and sex. 
In the third model, the effect of early life nutrition was examined after adjusting for BW-PGS, sex, and the first 
two PCs. In models two and four, interaction terms were added to models one and three to investigate effect 
modification of breastfeeding by POBW and BW-PGS, respectively.
In outcomes where the effect of early life nutrition was moderated by POBW or BW-PGS, breastfeeding, the 
moderator term (POBW or BW-PGS), and the specific adult outcome were examined as dichotomised variables 
and analysed using multivariate logistic regression.
Lastly, the potential for the moderation effects of sex on adult outcomes were ascertained by examining the 
interaction between sex and early life nutrition, and sensitivity analyses were performed by repeating the analyses 
after imputing the phenotype dataset using Multiple Imputation by Chain Equations (MICE)36.
All data were analysed using R and its associated  libraries37.
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